Loperamide Grindeks
Loperamide hydrochloride 2 mg hard capsules – antidiarrheal agent
Quick facts about Loperamide Grindeks
Key takeaways about Loperamide Grindeks
- Effective antidiarrheal: Loperamide reduces stool frequency and increases consistency by slowing intestinal motility and reducing fluid secretion
- Do not exceed recommended dose: High doses can cause serious cardiac side effects including QT prolongation and cardiac arrest
- Not for all types of diarrhea: Do not use if you have bloody diarrhea with fever (dysentery), acute ulcerative colitis, or antibiotic-associated colitis
- Seek medical advice if symptoms persist: If acute diarrhea does not improve within 48 hours, consult a healthcare professional
- Stay hydrated: Loperamide treats symptoms but does not replace lost fluids – oral rehydration is essential alongside treatment
What Is Loperamide Grindeks and What Is It Used For?
Loperamide Grindeks is an antidiarrheal medicine containing loperamide hydrochloride 2 mg. It is used to treat symptoms of acute (sudden-onset) diarrhea in adults and adolescents aged 12 years and older. It is also prescribed for chronic diarrhea associated with conditions such as inflammatory bowel disease and irritable bowel syndrome.
Loperamide belongs to a class of medicines known as antidiarrheal agents. Although it is chemically related to opioids, loperamide acts almost exclusively on opioid receptors in the gut wall and does not cross the blood-brain barrier in significant amounts at recommended doses. This means it provides effective relief from diarrhea without causing the central nervous system effects (such as pain relief or euphoria) associated with other opioid medications.
The active ingredient, loperamide hydrochloride, works through several complementary mechanisms. It binds to mu-opioid receptors in the myenteric plexus of the large intestine, which reduces the circular and longitudinal smooth muscle contractions (peristalsis) that propel contents through the bowel. By slowing intestinal transit, loperamide allows more time for water and electrolytes to be absorbed from the intestinal contents, resulting in firmer stools and reduced stool frequency.
Additionally, loperamide reduces the volume of secretions in the intestinal lumen and increases the tone of the anal sphincter, which helps prevent urgency and incontinence. These combined effects make loperamide one of the most effective and widely used antidiarrheal agents globally. The World Health Organization (WHO) includes loperamide on its Model List of Essential Medicines, recognizing its importance in treating diarrheal conditions worldwide.
Indications for use
Loperamide Grindeks is indicated for the following conditions:
- Acute diarrhea: Short-term symptomatic treatment of sudden-onset diarrhea in adults and adolescents aged 12 years and older, including traveler's diarrhea
- Chronic diarrhea: Long-term management of chronic diarrhea associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis in remission), irritable bowel syndrome with diarrhea predominance (IBS-D), and other conditions causing persistent loose stools
- Ileostomy management: Reduction of stool output in patients with an ileostomy, helping to improve quality of life and prevent dehydration
Loperamide treats the symptoms of diarrhea but does not address the underlying cause or replace lost fluids and electrolytes. Adequate oral rehydration is essential, especially in vulnerable populations such as the elderly and those with significant fluid loss. The WHO recommends oral rehydration salts (ORS) as the foundation of diarrhea treatment alongside symptomatic relief.
What Should You Know Before Taking Loperamide Grindeks?
Do not take Loperamide Grindeks if you have bloody diarrhea with fever, acute ulcerative colitis, antibiotic-associated pseudomembranous colitis, or bacterial dysentery. Use with caution in liver disease and always stay well hydrated during treatment.
Contraindications
You must not take Loperamide Grindeks if any of the following apply to you:
- Hypersensitivity: You are allergic to loperamide hydrochloride or any of the other ingredients in the capsule
- Dysentery: You have bloody diarrhea accompanied by a high fever, which may indicate infection with invasive bacteria such as Salmonella, Shigella, or Campylobacter
- Acute ulcerative colitis: You have an acute flare of ulcerative colitis, as loperamide may increase the risk of toxic megacolon
- Pseudomembranous colitis: You have diarrhea associated with broad-spectrum antibiotic use, which could indicate Clostridioides difficile infection
- Bacterial enterocolitis: Your diarrhea is caused by invasive organisms where slowing gut motility could worsen the condition
- Ileus: You have intestinal obstruction or conditions where inhibition of peristalsis should be avoided
- Age under 12 years: Loperamide Grindeks capsules should not be used in children under 12 without medical supervision
Warnings and Precautions
Talk to your doctor or pharmacist before taking Loperamide Grindeks if you have any of the following conditions:
- Liver impairment: Loperamide is extensively metabolized by the liver. Patients with hepatic dysfunction may have significantly increased bioavailability and are at higher risk of central nervous system toxicity. Dose reduction and careful monitoring are required
- AIDS-related diarrhea: If abdominal distension develops during treatment, loperamide should be discontinued immediately due to the rare risk of toxic megacolon
- Cardiac conditions: At supratherapeutic doses, loperamide has been associated with QT prolongation, Torsades de Pointes, and other serious cardiac arrhythmias, including cases resulting in cardiac arrest and death. Do not exceed the recommended dose
- Dehydration: Loperamide should not be used as a substitute for appropriate fluid and electrolyte replacement therapy
The FDA and EMA have issued safety warnings about serious cardiac events associated with loperamide misuse at doses higher than recommended. Never exceed the maximum recommended daily dose of 16 mg. Cases of QT prolongation, Torsades de Pointes, ventricular tachycardia, and cardiac arrest – including fatalities – have been reported. If you experience palpitations, dizziness, or fainting while taking loperamide, seek medical attention immediately.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy: Epidemiological studies in humans have not demonstrated an increased risk of congenital malformations with loperamide use during the first trimester. However, as with all medicines, loperamide should be used during pregnancy only if the potential benefit justifies the potential risk. Oral rehydration therapy is generally preferred as first-line treatment for diarrhea during pregnancy.
Breastfeeding: Small amounts of loperamide may pass into breast milk, although the levels are very low. Short-term use at recommended doses is generally considered compatible with breastfeeding according to most drug reference sources. However, consult your healthcare provider before use, particularly during the neonatal period or with prolonged therapy.
How Does Loperamide Grindeks Interact with Other Drugs?
Loperamide interacts with P-glycoprotein inhibitors (such as quinidine, ritonavir, and itraconazole) which can significantly increase its systemic exposure and risk of cardiac effects. It may also interact with desmopressin, increasing plasma levels of desmopressin by up to three-fold.
Drug interactions with loperamide are primarily related to its metabolism and transport across biological membranes. Loperamide is a substrate of P-glycoprotein (P-gp), which normally limits its absorption and keeps plasma levels low. When co-administered with P-gp inhibitors, loperamide levels in the blood can increase significantly, potentially leading to central nervous system effects and cardiac toxicity.
Additionally, loperamide is metabolized by cytochrome P450 enzymes (primarily CYP3A4 and CYP2C8) in the liver. Inhibitors of these enzymes can further increase systemic loperamide exposure. The combination of both P-gp and CYP inhibition represents the highest risk for clinically significant interactions.
| Interacting Drug | Mechanism | Effect | Severity |
|---|---|---|---|
| Quinidine | P-gp inhibitor | Increases loperamide CNS exposure 2–3 fold | Major – Avoid combination |
| Ritonavir | P-gp and CYP3A4 inhibitor | Significantly increases systemic loperamide levels | Major – Avoid combination |
| Itraconazole | P-gp and CYP3A4 inhibitor | Increases loperamide plasma concentration by 3–4 fold | Major – Avoid combination |
| Ketoconazole | CYP3A4 inhibitor | Increases systemic loperamide exposure | Moderate – Use with caution |
| Gemfibrozil | CYP2C8 inhibitor | Increases loperamide AUC by approximately 2-fold | Moderate – Use with caution |
| Desmopressin (oral) | Increased absorption | Increases desmopressin plasma levels by up to 3-fold | Moderate – Monitor closely |
| Cimetidine | CYP inhibitor | No clinically significant interaction observed | Minor – No action needed |
Major Interactions
The most clinically significant interactions involve drugs that inhibit P-glycoprotein (P-gp). Quinidine, when co-administered with loperamide, has been shown to increase respiratory depression markers in clinical studies, indicating that loperamide can cross the blood-brain barrier when P-gp is inhibited. Ritonavir and itraconazole, which inhibit both P-gp and CYP3A4, cause the most pronounced increases in systemic loperamide levels and should generally be avoided in combination with loperamide.
Concomitant use of loperamide with oral desmopressin results in a three-fold increase in plasma levels of desmopressin, likely due to slower gastrointestinal motility increasing desmopressin absorption. This interaction may increase the risk of hyponatremia, particularly in children and elderly patients.
Minor Interactions
Cimetidine, despite being an enzyme inhibitor, does not produce clinically significant changes in loperamide pharmacokinetics. Co-administration with cholestyramine may theoretically reduce loperamide absorption, but this interaction is not usually considered clinically relevant. Loperamide does not appear to significantly alter the pharmacokinetics of other drugs when used at recommended doses.
What Is the Correct Dosage of Loperamide Grindeks?
For acute diarrhea in adults: take 4 mg (two capsules) initially, then 2 mg (one capsule) after each loose stool, up to a maximum of 16 mg (eight capsules) per day. For chronic diarrhea: the usual maintenance dose is 4–8 mg daily. Do not exceed the maximum daily dose.
Adults
Acute Diarrhea
Initial dose: 4 mg (two capsules) taken at once.
Subsequent doses: 2 mg (one capsule) after each subsequent loose stool.
Maximum daily dose: 16 mg (eight capsules) per day.
Duration: Treatment should not normally exceed 48 hours. If symptoms persist beyond this time, seek medical advice as further investigation may be needed.
Chronic Diarrhea
Initial dose: 4 mg (two capsules) taken at once.
Maintenance dose: Typically 4–8 mg (two to four capsules) daily, adjusted according to response.
Maximum daily dose: 16 mg (eight capsules) per day.
Duration: Under medical supervision, loperamide may be used long-term for chronic diarrhea. Regular reassessment of the need for continued treatment is recommended.
Children
Children aged 12 years and older
The dose is the same as for adults. Always follow the prescriber's instructions. Loperamide Grindeks 2 mg capsules should not be used in children under 12 years of age without specific medical supervision.
The WHO advises against the use of loperamide in young children, particularly those under 3 years of age, due to the risk of serious adverse effects including central nervous system depression, paralytic ileus, and death. Oral rehydration solutions (ORS) are the recommended first-line treatment for diarrhea in young children. If loperamide is prescribed by a physician for children aged 6–12, strict dose calculation based on body weight is required.
Elderly
No dose adjustment is generally required in elderly patients. However, elderly patients may be more susceptible to the effects of dehydration caused by diarrhea, and particular attention should be paid to maintaining adequate fluid intake. Loperamide should be used with caution in elderly patients with hepatic impairment, as reduced first-pass metabolism may increase systemic exposure.
Missed Dose
Loperamide is taken on an as-needed basis (after each loose stool), so a missed dose is generally not applicable. If you are taking it on a regular schedule for chronic diarrhea and miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Overdose
Loperamide overdose is a medical emergency. Symptoms of overdose may include:
- Central nervous system depression: Stupor, impaired coordination, drowsiness, miosis (constricted pupils), muscular hypertonia, and respiratory depression
- Cardiac effects: QT interval prolongation, Torsades de Pointes, wide complex tachycardia, ventricular fibrillation, cardiac arrest. These cardiac effects have been associated with fatalities
- Gastrointestinal effects: Constipation, nausea, paralytic ileus
If overdose is suspected, seek emergency medical attention immediately. Naloxone can be used as an antidote for CNS depression. Due to the long duration of action of loperamide (up to 24 hours or longer) compared to naloxone (1–3 hours), repeated doses of naloxone may be necessary. Continuous cardiac monitoring for at least 48 hours is recommended following significant overdose, as cardiac effects may be delayed.
| Patient Group | Indication | Initial Dose | Maximum Daily Dose |
|---|---|---|---|
| Adults | Acute diarrhea | 4 mg, then 2 mg after each loose stool | 16 mg (8 capsules) |
| Adults | Chronic diarrhea | 4 mg, then adjust to response | 16 mg (8 capsules) |
| Adolescents (12+) | Acute diarrhea | 4 mg, then 2 mg after each loose stool | 16 mg (8 capsules) |
| Children (<12 years) | Not recommended | Only under medical supervision | Physician-determined |
| Elderly | Same as adults | Same as adults | 16 mg – monitor hydration |
What Are the Side Effects of Loperamide Grindeks?
The most common side effects of Loperamide Grindeks are headache, constipation, nausea, dizziness, and flatulence. Serious but rare side effects include paralytic ileus, toxic megacolon, and – at supratherapeutic doses – cardiac arrhythmias. Most side effects at recommended doses are mild and self-limiting.
Like all medicines, Loperamide Grindeks can cause side effects, although not everybody gets them. At recommended doses, loperamide is generally well tolerated. The side effects listed below are based on post-marketing surveillance data, clinical trials, and regulatory safety reviews from the EMA and FDA.
The frequency categories below follow the international convention used by the European Medicines Agency (EMA):
Common
- Headache
- Constipation
- Nausea
- Flatulence (gas)
- Dizziness
Uncommon
- Abdominal pain or cramping
- Dry mouth
- Vomiting
- Dyspepsia (indigestion)
- Drowsiness
- Skin rash
Rare
- Abdominal distension
- Paralytic ileus (intestinal paralysis)
- Urinary retention
- Fatigue
- Hypersensitivity reactions (including urticaria, pruritus, angioedema)
- Stevens-Johnson syndrome (very rare)
- Toxic epidermal necrolysis (very rare)
- Bullous eruptions including erythema multiforme
Not known frequency (from post-marketing reports)
- Toxic megacolon (primarily in patients with acute colitis)
- Loss of consciousness (at supratherapeutic doses)
- QT prolongation and cardiac arrhythmias (at supratherapeutic doses)
- Miosis (constricted pupils)
- Hypertonia (increased muscle tone)
Stop taking Loperamide Grindeks and seek immediate medical attention if you experience: severe constipation with abdominal bloating, signs of an allergic reaction (difficulty breathing, swelling of face or throat, severe skin rash), palpitations, dizziness or fainting (which may indicate a cardiac rhythm disturbance), or fever with worsening diarrhea.
It is important to distinguish side effects from the underlying illness being treated. Abdominal discomfort, for example, may be related to the diarrheal condition rather than the medication. If you experience constipation, reduce the dose or stop taking loperamide temporarily. Report any unexpected or severe side effects to your healthcare provider or national pharmacovigilance authority.
How Should You Store Loperamide Grindeks?
Store Loperamide Grindeks at room temperature below 25°C in the original packaging. Keep out of the reach and sight of children. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to maintain their effectiveness and safety. Follow these guidelines for Loperamide Grindeks:
- Temperature: Store below 25°C (77°F). Do not freeze
- Light and moisture: Store in the original packaging to protect from light and moisture
- Children: Keep out of the reach and sight of children. Store in a secure location
- Expiry date: Do not use this medicine after the expiry date stated on the carton and blister pack. The expiry date refers to the last day of that month
- Disposal: Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment
If capsules have changed in appearance (discoloration, crumbling, unusual odor), do not use them and consult your pharmacist for replacement. Check expiry dates periodically and dispose of any expired medicines appropriately through pharmacy take-back programs or other designated disposal routes available in your country.
What Does Loperamide Grindeks Contain?
Each Loperamide Grindeks hard capsule contains 2 mg of loperamide hydrochloride as the active substance. Excipients include lactose monohydrate, maize starch, and magnesium stearate. The capsule shell contains gelatin and coloring agents.
Understanding what your medicine contains is important, particularly if you have known allergies or intolerances to specific excipients.
Active substance
Each hard capsule contains 2 mg of loperamide hydrochloride, equivalent to approximately 1.74 mg of loperamide base. Loperamide hydrochloride is a white to slightly yellow crystalline powder that is practically insoluble in water.
Excipients (inactive ingredients)
The capsule contents typically include:
- Lactose monohydrate: A filler used to provide bulk to the capsule contents. Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine
- Maize starch (corn starch): A disintegrant that helps the capsule contents disperse after ingestion
- Magnesium stearate: A lubricant used in the manufacturing process
- Talc: A flow agent that improves capsule filling consistency
Capsule shell
The hard capsule shell is typically composed of:
- Gelatin: Forms the basic structure of the capsule. Not suitable for strict vegetarians or vegans
- Coloring agents: Including titanium dioxide (E171), iron oxide yellow (E172), and/or other approved colorants depending on the specific product presentation
This medicine contains lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The amount of lactose per capsule is small, but patients with severe lactose intolerance should discuss this with their healthcare provider.
Frequently Asked Questions About Loperamide Grindeks
Loperamide Grindeks is classified as a prescription-only medicine (Rx). However, loperamide is available over the counter (OTC) in many countries under various brand names and in lower pack sizes. The prescription requirement varies by country, formulation, and pack size. In the United States, for example, loperamide is available OTC as Imodium A-D, while in some European countries, pharmacists may dispense it without a prescription for short-term use. Check your local regulations or ask your pharmacist.
Loperamide typically begins to work within 1 to 3 hours after taking the first dose. Most patients notice a reduction in stool frequency and improved stool consistency within the first few hours. The peak effect is usually reached within 16 to 24 hours of starting treatment. For acute diarrhea, significant improvement is often seen within the first day of treatment. The duration of action of a single dose is approximately 4 to 6 hours, though this can vary between individuals.
Loperamide should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Available epidemiological data from studies involving over 600 first-trimester exposures have not shown an increased risk of congenital malformations. However, human data remains limited. Oral rehydration therapy is generally preferred as first-line treatment for diarrhea in pregnancy. If an antidiarrheal is necessary, your doctor can assess whether loperamide is appropriate for your specific situation. Always consult your healthcare provider before using any medication during pregnancy.
Loperamide Grindeks 2 mg capsules should not be used in children under 12 years of age without medical supervision. For adolescents aged 12 and older, the dosing is the same as for adults. The World Health Organization (WHO) advises against the use of loperamide in young children, particularly those under 3 years, due to the risk of serious central nervous system effects. Oral rehydration solutions (ORS) are the recommended first-line treatment for childhood diarrhea. If your child has persistent or severe diarrhea, consult a pediatrician rather than self-medicating.
Loperamide overdose can cause serious and potentially fatal effects including QT prolongation, Torsades de Pointes, and cardiac arrest. If you suspect an overdose, seek emergency medical attention immediately by calling your local emergency number. Do not wait for symptoms to develop, as cardiac effects can be delayed. Treatment may include naloxone as an antidote for CNS and respiratory depression, continuous cardiac monitoring for at least 48 hours, and supportive care. The FDA has issued warnings about serious heart problems associated with loperamide misuse at doses higher than recommended.
For acute diarrhea, do not take loperamide for more than 48 hours without consulting a doctor. If symptoms do not improve within 48 hours, seek medical advice as this may indicate an underlying condition requiring different treatment. For chronic diarrhea (such as in irritable bowel syndrome or inflammatory bowel disease), loperamide may be used long-term under medical supervision. Your doctor will regularly reassess whether continued treatment is appropriate. Long-term use at recommended doses has been shown to be generally safe and well-tolerated in clinical studies.
References
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023. Available from: www.who.int
- European Medicines Agency. Loperamide-containing medicinal products – Article 31 referral. EMA/175763/2017. London: EMA; 2017.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious heart problems with high doses of the antidiarrheal medicine loperamide (Imodium), including from abuse and misuse. Silver Spring, MD: FDA; 2016 (updated 2018).
- Hanauer SB. The role of loperamide in gastrointestinal disorders. Reviews in Gastroenterological Disorders. 2008;8(1):15–20.
- Baker DE. Loperamide: a pharmacological review. Reviews in Gastroenterological Disorders. 2007;7(Suppl 3):S11–18.
- Regnard C, et al. Loperamide. Journal of Pain and Symptom Management. 2011;42(2):319–323. doi:10.1016/j.jpainsymman.2011.06.001
- American College of Gastroenterology. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17–44. doi:10.14309/ajg.0000000000001036
- British National Formulary (BNF). Loperamide hydrochloride. London: BMJ Group and Pharmaceutical Press; 2025.
- Awouters F, et al. Loperamide. Survey of studies on mechanism of its antidiarrheal activity. Digestive Diseases and Sciences. 1993;38(6):977–995.
- Swank KA, et al. Loperamide abuse and misuse: a review of the literature. Journal of Forensic Sciences. 2017;62(4):1043–1052. doi:10.1111/1556-4029.13469
About the Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team, which includes specialists in clinical pharmacology, gastroenterology, and internal medicine. All content follows evidence-based medicine principles and adheres to the GRADE framework for evaluating medical evidence.
iMedic Medical Editorial Team – Specialists in Clinical Pharmacology and Gastroenterology
iMedic Medical Review Board – Independent panel following WHO, EMA, FDA, and BNF guidelines
Evidence standard: Level 1A – Based on systematic reviews, meta-analyses, and randomized controlled trials. All medical claims are referenced to peer-reviewed sources. Last fact-checked: .